CN Bio and Pharmaron seal new partnership
28 Apr 2025
Drug discovery and development workflow solutions provider CN Bio has announced a strategic partnership with life sciences R&D services company Pharmaron.
Pharmaron will validate CN Bio’s PhysioMimix technology across existing applications and aid integration of organ-on-a-chip technologies into its platform.
The initial collaboration will prioritise validation of CN Bio PhysioMimix technology for current applications in disease modelling, toxicity testing and absorption, distribution, metabolism and excretion (ADME) studies.
CN Bio chief scientific officer Dr Tomasz Kostrzewski (left) stated: “The developments this partnership will enable are especially important given the recent FDA announcement, outlining their plan to phase out animal testing requirement for monoclonal antibodies and other drugs with more human-relevant models.
“Together we can expedite this key development in line with global momentum for more ethical advancements that reduce costs and improve human health.”
Pharmaron CSO Dr Hua Yang (right) added his company was committed to continuous innovation that enhanced services and accelerated drug discovery and development.
“Organ-on-a-chip technology holds significant potential to advance translational science by improving our understanding of drugability at the preclinical stage,” he stated.
